Bharat Biotech on Friday announced a nearly 40 per cent reduction in the price of MOSQIVAC, the RTS,S/AS01 malaria vaccine.
In a post on social media platform X, Bharat Biotech said the move will help protect another 1 million children and generate USD 50 million in savings.
“Under an agreement executed by UNICEF and financially backed by Gavi, the vaccine price will be reduced by approximately 40 per cent,” the Hyderabad-based biotech company said in the post.
“Developed by GSK, RTS, S/AS01 is the world’s first malaria vaccine and is now manufactured by Bharat Biotech under the brand name MOSQIVAC®,” it said.
The need is urgent as one child dies from malaria every minute, the company added.
Published on October 23, 2026
